奈达铂联合吉西他滨治疗晚期复治肺鳞癌的临床观察

目的 观察奈达铂联合吉西他滨治疗晚期复治肺鳞癌的疗效和毒性反应。方法 26例经病理组织学或细胞学检查确诊的晚期肺鳞癌复治患者，给予奈达铂80mg／m2 d1，吉西他滨1000mg／m2 d1、d8， 21天为1周期。1～2周期后评价疗效及毒性反应，并随访患者无进展生存时间（PFS）。结果 26例患者中23例可评价疗效，无完全缓解（CR）病例，部分缓解（PR） 6例，稳定（SD） 12例，进展（PD） 5例，总有效率（RR）为261％，临床获益率（DCR）为 783％。中位PFS 为4个月。主要毒副反应为骨髓抑制、肝功能损害和胃肠道反应，骨髓抑制明显但可耐受。结论 奈达铂联合吉西他滨治疗晚期复治肺鳞癌疗效确切，毒副反应可耐受，值得进一步推广研究。

Clinical observation of nedaplatin combined with gemcitabine for recurative advanced lung squamous carcinoma

Objective To observe the efficacy and safety of nedaplatin combined with gemcitabine for advanced multipletreatment after failure of squamous cell lung cancer.Methods Twenty-six advanced multiple-treatment patients were enrolled in this study with histologically or cytologically diagnosed as squamous cell carcinoma,which were given nedaplatin 80mg/m2 d1,gemcitabine 1000mg/m2,d1 and d8.Twenty-one days was a cycle.Efficacy and toxicity were evaluated after 1-2 cycles,and progression-free survival（PFS） was observed.Results Twenty-three patients were available for efficacy,with no complete remission cases,6 cases of partial remission,12 cases of stable and 5 cases of progress.Total response rate was 26.1%,the clinical benefit rate was 78.3%.The median PFS was 4 months.Major toxicities were liver damage and gastrointestinal tract,myelosuppression was obvious but can be tolerated.Conclusion Nedaplatin combined with gemcitabine in advanced multiple-treatment after failure of squamous cell lung cancer is efficacy.The toxicity can be tolerated,worthy of further dissemination and research.